ADC Therapeutics (ADCT) Net Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly Net Margin of 158.11% for Q1 2026, up 948.0% year-on-year from 15.09% in Q1 2025, and up 36.6% on a QoQ basis from 249.38% in Q3 2025.
ADC Therapeutics (ADCT) Net Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Net Margin for 6 consecutive years, with 158.11% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 472.06 Bn | 467.27 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 122.10 Bn | 114.85 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.25 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 30.33% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.50 Bn | 959.66 Mn | 17.65% |
| 10 | ADC Therapeutics | 176.49 Mn | -54.52 Mn | 17.38 Mn | -158.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -158.11% |
| Sep 30, 2025 | -249.38% |
| Jun 30, 2025 | -300.68% |
| Mar 31, 2025 | -167.59% |
| Sep 30, 2024 | -236.73% |
| Jun 30, 2024 | -206.47% |
| Mar 31, 2024 | -254.81% |
| Sep 30, 2023 | -312.58% |
| Jun 30, 2023 | -249.96% |
| Mar 31, 2023 | -312.90% |
| Sep 30, 2022 | -66.31% |
| Jun 30, 2022 | -372.30% |
| Mar 31, 2022 | -35.83% |
| Sep 30, 2021 | -544.22% |
| Jun 30, 2021 | -1,930.03% |